DE68929077T2 - Transplantieren von genetisch modifizierten zellen zur behandlung von krankheiten des zentralen nervensystems - Google Patents

Transplantieren von genetisch modifizierten zellen zur behandlung von krankheiten des zentralen nervensystems

Info

Publication number
DE68929077T2
DE68929077T2 DE68929077T DE68929077T DE68929077T2 DE 68929077 T2 DE68929077 T2 DE 68929077T2 DE 68929077 T DE68929077 T DE 68929077T DE 68929077 T DE68929077 T DE 68929077T DE 68929077 T2 DE68929077 T2 DE 68929077T2
Authority
DE
Germany
Prior art keywords
nervous system
central nervous
genetically modified
treating diseases
modified cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68929077T
Other languages
English (en)
Other versions
DE68929077D1 (de
Inventor
Fred Gage
Michael Rosenberg
John Wolff
Theodore Friedman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of DE68929077D1 publication Critical patent/DE68929077D1/de
Publication of DE68929077T2 publication Critical patent/DE68929077T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/48Nerve growth factor [NGF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0071Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1025Acyltransferases (2.3)
    • C12N9/1029Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y114/00Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16002Tyrosine 3-monooxygenase (1.14.16.2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/13011Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/948Microorganisms using viruses or cell lines
DE68929077T 1988-12-15 1989-12-12 Transplantieren von genetisch modifizierten zellen zur behandlung von krankheiten des zentralen nervensystems Expired - Lifetime DE68929077T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/285,196 US5082670A (en) 1988-12-15 1988-12-15 Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
PCT/US1989/005557 WO1990006757A1 (en) 1988-12-15 1989-12-12 Grafting genetically modified cells to treat diseases of the central nervous system

Publications (2)

Publication Number Publication Date
DE68929077D1 DE68929077D1 (de) 1999-10-28
DE68929077T2 true DE68929077T2 (de) 2000-05-25

Family

ID=23093180

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68929077T Expired - Lifetime DE68929077T2 (de) 1988-12-15 1989-12-12 Transplantieren von genetisch modifizierten zellen zur behandlung von krankheiten des zentralen nervensystems

Country Status (7)

Country Link
US (1) US5082670A (de)
EP (1) EP0449948B1 (de)
JP (1) JPH04503351A (de)
AT (1) ATE184797T1 (de)
CA (1) CA2005567C (de)
DE (1) DE68929077T2 (de)
WO (1) WO1990006757A1 (de)

Families Citing this family (262)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048729A (en) * 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6544771B1 (en) 1987-12-11 2003-04-08 Cell Genesys, Inc. Retroviral gene therapy vectors and therapeutic methods based thereon
EP0732397A3 (de) 1988-02-05 1996-10-23 Whitehead Institute For Biomedical Research Modifizierte Hepatozyten und deren Verwendungen
US5580776A (en) * 1988-02-05 1996-12-03 Howard Hughes Medical Institute Modified hepatocytes and uses therefor
US5650148A (en) * 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
US7238673B2 (en) * 1989-03-31 2007-07-03 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
AU7312891A (en) * 1990-02-12 1991-09-03 Board Of Regents, The University Of Texas System Satellite cell proliferation in adult skeletal muscle
FR2662698A1 (fr) * 1990-06-05 1991-12-06 Centre Nat Rech Scient Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.
US5269785A (en) * 1990-06-28 1993-12-14 Bonutti Peter M Apparatus and method for tissue removal
US5849571A (en) * 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5849572A (en) * 1990-10-10 1998-12-15 Regents Of The University Of Michigan HSV-1 vector containing a lat promoter
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
WO1992007945A1 (en) * 1990-10-30 1992-05-14 Dana Farber Cancer Institute Cell type specific alteration of levels of gene products in neural cells
AU9179591A (en) * 1990-12-26 1992-08-17 Howard Hughes Medical Center Modified hepatocytes and uses therefor
US5800829A (en) * 1991-04-25 1998-09-01 Brown University Research Foundation Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core
ES2107537T3 (es) * 1991-04-25 1997-12-01 Univ Brown Res Found Vehiculo inmunoaislante biocompatible implantable para suministrar productos terapeuticos seleccionados.
US6071889A (en) * 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
US7361505B1 (en) 1991-07-08 2008-04-22 Neurospheres Holdings Ltd. Multipotent neural stem cell compositions
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5851832A (en) * 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US6497872B1 (en) * 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
US5980885A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
US6399369B1 (en) 1991-07-08 2002-06-04 Neurospheres Holdings Ltd. Multipotent neural stem cell cDNA libraries
WO1994016718A1 (en) * 1991-07-08 1994-08-04 Neurospheres Ltd. Genetic modification of neural stem cells
US7166277B1 (en) * 1991-07-08 2007-01-23 Neurospheres Holdings Ltd. Remyelination of neurons using multipotent neural stem cell progeny
US6294346B1 (en) 1991-07-08 2001-09-25 Neurospheres Holdings, Ltd. Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents
US5329846A (en) * 1991-08-12 1994-07-19 Bonutti Peter M Tissue press and system
US6503277B2 (en) 1991-08-12 2003-01-07 Peter M. Bonutti Method of transplanting human body tissue
US5529774A (en) * 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
US6214334B1 (en) * 1991-10-21 2001-04-10 Trustees Of The University Of Pennsylvania Compositions and methods for producing and using homogenous neuronal cell transplants to treat neurodegenerative disorders and brain and spinal cord injuries
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6692737B1 (en) 1991-11-05 2004-02-17 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6054288A (en) * 1991-11-05 2000-04-25 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
NZ245015A (en) * 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
DE69228127T2 (de) * 1991-11-15 1999-09-02 Univ California Therapie des zentralnervensystems mit genetisch modifizierten zellen
JPH07503467A (ja) * 1992-01-23 1995-04-13 ニューヨーク ユニヴァーシティー 細胞を脳に移植する方法及びその治療使用
EP0584339A4 (en) * 1992-03-04 1996-02-28 Jon A Wolff Method of delivering therapeutic substances to the brain
US6087323A (en) * 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
US5688936A (en) * 1992-06-11 1997-11-18 The Regents Of The University Of California Vesicle membrane transport proteins
WO1994001135A1 (en) * 1992-07-06 1994-01-20 The Research Foundation Of State University Of New York Method of producing genetically modified astrocytes and uses thereof
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
US6531124B1 (en) 1992-07-10 2003-03-11 Transkaryotic Therapies, Inc. In vivo production and delivery of insulinotropin for gene therapy
US5266588A (en) * 1992-09-25 1993-11-30 Bristol-Myers Squibb Company Compound produced by a strain of microtetraspora having antibacterial and neuritogenic activity
ATE404683T1 (de) * 1992-09-25 2008-08-15 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
US5766948A (en) 1993-01-06 1998-06-16 The Regents Of The University Of California Method for production of neuroblasts
ES2170096T3 (es) * 1993-04-13 2002-08-01 Us Gov Health & Human Serv Uso de lineas celulares fetales neuroderivadas para terapia de trasplantes.
US5753491A (en) * 1993-04-13 1998-05-19 Us Health Use of neuro-derived fetal cell lines for transplantation therapy
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
FR2707091B1 (fr) 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
US5908623A (en) * 1993-08-12 1999-06-01 Cytotherapeutics, Inc. Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
ATE218893T1 (de) * 1993-08-12 2002-06-15 Neurotech Sa Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten
EP0728194B1 (de) * 1993-11-09 2003-01-08 Neurospheres Holdings Ltd. In situ modifikation und manipulation von stammzellen des zentralen nervensystems
CA2146735C (en) * 1994-04-11 2007-02-20 Chise Tateno Liver parenchymal cells having clonal growth ability, method for obtaining same, method for subculturing same, and subculturing system of primary hepatocytes
US5714353A (en) * 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
FR2721943B1 (fr) * 1994-06-29 1996-08-02 Rhone Poulenc Rorer Sa Adenovirus comprenant un gene codant pour une superoxyde dismutase
US5834029A (en) * 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
US5858747A (en) * 1994-07-20 1999-01-12 Cytotherapeutics, Inc. Control of cell growth in a bioartificial organ with extracellular matrix coated microcarriers
US5935849A (en) * 1994-07-20 1999-08-10 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
FR2723588B1 (fr) * 1994-08-12 1996-09-20 Rhone Poulenc Rorer Sa Adenovirus comprenant un gene codant pour la glutathion peroxydase
US6103226A (en) * 1994-08-12 2000-08-15 Arch Development Corporation Genetically engineered cells that produce produce L. Dopa
EP0787013A4 (de) * 1994-10-19 1999-11-24 Human Genome Sciences Inc Menschliche hypoxanthin(-guanin) phosphorribosyl transferase-2
DE69535830D1 (de) 1994-11-02 2008-10-16 Trophix Pharm Inc Natrium-ionenkanäle spezifisch für das periphäre nervensystem, dna welche diese kodiert, wirkstoff-suche und methoden zu deren herstellung und verwendung
US6277372B1 (en) * 1994-11-08 2001-08-21 Diacrin, Inc. Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases
US6204053B1 (en) 1994-11-08 2001-03-20 Diacrin, Inc. Porcine cortical cells and their use in treatment of neurological deficits due to neurodegenerative diseases
US6294383B1 (en) 1994-11-08 2001-09-25 The Mclean Hospital Corporation Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases
FR2727429B1 (fr) 1994-11-30 1997-11-28 Haguenauer Odile Cohen Lignees d'encapsidation et vecteurs d'expression pour la transcomplementation de vecteurs retroviraux defectifs
AU705932B2 (en) * 1995-03-13 1999-06-03 University Of South Florida Sertoli cells as neurorecovery inducing cells for neurodegenerative disorders
US5702700A (en) * 1995-03-13 1997-12-30 University Of South Florida Sertoli cells as neurorecovery inducing cells for Parkinson's disease
US5681744A (en) * 1995-03-17 1997-10-28 Greenstein; Robert J. Delivery and expression of heterologus genes using upstream enhancer regions of mammalian gene promoters
US6653134B2 (en) * 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
US6974571B2 (en) * 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US6576607B1 (en) * 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
WO1996033264A1 (en) * 1995-04-20 1996-10-24 University Of South Florida Purified and isolated sertoli cell aggregate
US5849585A (en) * 1995-05-10 1998-12-15 Genetech, Inc. Isolating and culturing Schwann cells
US5714385A (en) * 1995-05-10 1998-02-03 Genentech, Inc. Media for culturing schwann cells
US5721139A (en) * 1995-05-10 1998-02-24 Genentech, Inc. Isolating and culturing schwann cells
US6033660A (en) * 1995-05-10 2000-03-07 Genentech, Inc. Method of treating a nervous system injury with cultured schwann cells
US6495364B2 (en) * 1995-05-23 2002-12-17 Neurotech, S.A. Mx-1 conditionally immortalized cells
CA2221604A1 (en) * 1995-06-06 1996-12-12 Andrew Freese Gene therapy for pituitary adenoma and other endocrine disorders
AU742824C (en) * 1995-06-06 2003-03-20 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Use of neuro-derived fetal cell lines for transplantation therapy
US6306649B1 (en) * 1995-06-27 2001-10-23 Ariad Gene Therapeutics, Inc. Heterologous transcription factors
US5753505A (en) * 1995-07-06 1998-05-19 Emory University Neuronal progenitor cells and uses thereof
US5800812A (en) * 1995-09-15 1998-09-01 Yeda Research And Development Co. Ltd. Methods of use of mononuclear phagocytes to promote axonal regeneration
US6267955B1 (en) 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
US20020006660A1 (en) * 1996-03-01 2002-01-17 Rhone-Poulenc Rorer, S.A. Genetically-modified neural progenitors and uses thereof
AU1979897A (en) * 1996-03-04 1997-09-22 University Of Medicine And Dentistry Of New Jersey Genetically engineered primary oligodendrocytes for transplantation-mediated gene delivery in the central nervous system
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
US6037175A (en) * 1996-03-12 2000-03-14 The University Of South Florida Method and media for enhancing cryopreservation of cells
US7544511B2 (en) * 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
US6759499B1 (en) * 1996-07-16 2004-07-06 Exxonmobil Chemical Patents Inc. Olefin polymerization process with alkyl-substituted metallocenes
US5718717A (en) * 1996-08-19 1998-02-17 Bonutti; Peter M. Suture anchor
US6713247B1 (en) 1996-09-03 2004-03-30 Signal Pharmaceuticials, Inc. Human CNS cell lines and methods of use therefor
US20040086494A1 (en) * 1996-10-07 2004-05-06 John Constance Mary Immune privileged cells for delivery of proteins and peptides
US20020123471A1 (en) * 1997-03-06 2002-09-05 Klaus Uberla Lentivirus based vector and vector system
ATE426018T1 (de) * 1997-04-10 2009-04-15 Stichting Katholieke Univ Pca3, pca3-gene und verfahren zu ihrer verwendung
IT1292017B1 (it) * 1997-05-28 1999-01-25 Dompe Spa Composizioni farmaceutiche contenenti la proteina stimolante i macrofagi per il trattamento di patologie del sistema nervoso
ATE246935T1 (de) * 1997-06-11 2003-08-15 Acorda Therapeutics Zns neuroregenerative zusammensetzungen und deren verwendungen
US20030121064A1 (en) * 1997-06-11 2003-06-26 Ann Logan CNS neuroregenerative compositions and methods of use
WO1998056393A1 (en) * 1997-06-13 1998-12-17 University Technology Corporation Transplantation of immortalized dopamine cells to improve neurological deficits
AU8180498A (en) * 1997-06-30 1999-01-19 Regents Of The University Of California, The Method for treatment of spinal cord injuries in a mammal
US6475230B1 (en) * 1997-08-01 2002-11-05 Peter M. Bonutti Method and apparatus for securing a suture
US20100081197A1 (en) * 1997-08-14 2010-04-01 Sylvie Roux In vivo modulation of neuronal transport
PT1049712E (pt) * 1997-08-14 2007-04-30 Pasteur Institut Proteínas híbridas da toxina do tétano que migram retrogradamente e trans - sinapticamente para o snc
US7923216B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport
US7923015B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur Methods for direct visualization of active synapses
US5968829A (en) * 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6093531A (en) * 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
US6045551A (en) 1998-02-06 2000-04-04 Bonutti; Peter M. Bone suture
AU762472B2 (en) * 1998-03-13 2003-06-26 University Of British Columbia, The Therapeutic chemokine receptor antagonists
CA2245224A1 (en) * 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
US7157435B2 (en) 1998-04-15 2007-01-02 The Regents Of The University Of California Methods for modulation of the effects of aging on the primate brain
US6815431B2 (en) 1998-04-15 2004-11-09 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
WO2002007774A2 (en) * 2000-07-19 2002-01-31 The Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US6683058B1 (en) 1998-04-15 2004-01-27 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US6451306B1 (en) 1998-04-15 2002-09-17 The Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US6171610B1 (en) 1998-04-24 2001-01-09 University Of Massachusetts Guided development and support of hydrogel-cell compositions
US6027744A (en) * 1998-04-24 2000-02-22 University Of Massachusetts Medical Center Guided development and support of hydrogel-cell compositions
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
WO2000006700A1 (en) * 1998-07-29 2000-02-10 Layton Bioscience, Inc. Production and use of dopaminergic cells to treat dopaminergic deficiencies
US6444205B2 (en) 1998-09-30 2002-09-03 Diacrin, Inc. Transplantation of neural cells for the treatment of chronic pain or spasticity
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
US8778899B2 (en) 1999-06-01 2014-07-15 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
DE19928210B4 (de) * 1999-06-19 2005-08-18 Neuroprogen Gmbh Leipzig Neuronales Zellmaterial und Verfahren zu dessen Herstellung
US6447516B1 (en) 1999-08-09 2002-09-10 Peter M. Bonutti Method of securing tissue
US6368343B1 (en) 2000-03-13 2002-04-09 Peter M. Bonutti Method of using ultrasonic vibration to secure body tissue
ES2260059T3 (es) * 1999-09-29 2006-11-01 Diagnocure Inc. Rna mensajero del pca3 en tejidos benignos y malignos de prostata.
US7560275B2 (en) * 1999-12-30 2009-07-14 Vbi Technologies, L.L.C. Compositions and methods for generating skin
US7575921B2 (en) * 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
US6635073B2 (en) 2000-05-03 2003-10-21 Peter M. Bonutti Method of securing body tissue
US20050059584A1 (en) * 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US7368425B2 (en) * 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US7378098B2 (en) * 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
CA2335109A1 (en) * 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
PT1272204E (pt) * 2000-04-14 2007-10-02 Univ Pittsburgh Aumento e enchimento de tecidos moles e osso utilizando células progenitoras derivadas de músculo, suas composições e tratamentos
US7037493B2 (en) 2000-05-01 2006-05-02 Cornell Research Foundation, Inc. Method of inducing neuronal production in the brain and spinal cord
US6897061B1 (en) 2000-06-16 2005-05-24 Spinal Cord Society Transdifferentiation of glial cells
JP4031901B2 (ja) * 2000-07-19 2008-01-09 株式会社東芝 固体撮像装置
WO2002057428A1 (en) * 2000-10-30 2002-07-25 University Of Massachusetts Isolation of spore-like cells from tissues exposed to extreme conditions
US20060280724A1 (en) * 2000-11-04 2006-12-14 Ferguson Ian A Identification of ligands that enable endocytosis, using in vivo manipulation of neuronal fibers
JP2004521877A (ja) * 2000-11-22 2004-07-22 ジェロン コーポレイション 多能性幹細胞の同種移植片の寛容化
US6921665B2 (en) * 2000-11-27 2005-07-26 Roslin Institute (Edinburgh) Selective antibody targeting of undifferentiated stem cells
US6576464B2 (en) * 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
US20040247571A1 (en) * 2001-04-23 2004-12-09 Xia Meijer Neural cells expressing tyrosine hydroxylase
US6719765B2 (en) 2001-12-03 2004-04-13 Bonutti 2003 Trust-A Magnetic suturing system and method
US7576065B2 (en) * 2002-02-15 2009-08-18 Cornell Research Foundation, Inc. Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
US8293488B2 (en) 2002-12-09 2012-10-23 Neuralstem, Inc. Method for screening neurogenic agents
EP1576134B1 (de) * 2002-12-09 2013-03-06 Judith Kelleher-Andersson Verfahren zur entdeckung neurogener wirkstoffe
US7789885B2 (en) * 2003-01-15 2010-09-07 Biomet Manufacturing Corp. Instrumentation for knee resection
US7837690B2 (en) * 2003-01-15 2010-11-23 Biomet Manufacturing Corp. Method and apparatus for less invasive knee resection
US7887542B2 (en) * 2003-01-15 2011-02-15 Biomet Manufacturing Corp. Method and apparatus for less invasive knee resection
US8551100B2 (en) 2003-01-15 2013-10-08 Biomet Manufacturing, Llc Instrumentation for knee resection
WO2004070056A2 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
WO2004098621A1 (en) * 2003-04-17 2004-11-18 U.S. Department Of Veterans Affairs Isolated/cloned human nt2 cell lines expressing serotonin and gaba
US7459152B2 (en) * 2003-04-23 2008-12-02 Rush University Medical Center Erythropoietin administration to improve graft survival
ES2354304T3 (es) 2003-04-25 2011-03-11 The University Of Pittsburgh Células derivadas del músculo (mdcs) para promover y potenciar la regeneración y reparación de nervios.
JP4926703B2 (ja) * 2003-07-03 2012-05-09 セルトリ・テクノロジーズ・エルエルシー セルトリ細胞および筋様細胞を含有する組成物、並びに細胞性移植における該組成物の使用
US7326571B2 (en) * 2003-07-17 2008-02-05 Boston Scientific Scimed, Inc. Decellularized bone marrow extracellular matrix
US20050013870A1 (en) * 2003-07-17 2005-01-20 Toby Freyman Decellularized extracellular matrix of conditioned body tissues and uses thereof
WO2005033297A1 (en) * 2003-09-19 2005-04-14 The Rockefeller University Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells
US20050070379A1 (en) * 2003-09-26 2005-03-31 Todd Gilmour Rite-Hite Golf Tee
US7488324B1 (en) * 2003-12-08 2009-02-10 Biomet Manufacturing Corporation Femoral guide for implanting a femoral knee prosthesis
WO2005095450A2 (en) 2004-03-30 2005-10-13 Nsgene A/S Therapeutic use of a growth factor, nsg33
AU2005252434B2 (en) 2004-06-09 2011-11-24 The University Court Of The University Of Edinburgh Neural stem cells
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32
EP1814979B1 (de) * 2004-11-17 2015-04-08 Neuralstem, Inc. Transplantation menschlicher nervenzellen zur behandlung neurodegenerativer erkrankungen
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
WO2006084284A2 (en) * 2005-01-31 2006-08-10 Cognate Therapeutics, Inc. Adipose derived adult stromal cells exhibiting characteristics of endothelial cells
US20070092449A1 (en) * 2005-04-05 2007-04-26 Rafael Vazquez-Martinez Methods for direct visualization of active synapses
US7695479B1 (en) 2005-04-12 2010-04-13 Biomet Manufacturing Corp. Femoral sizer
TW200726474A (en) * 2005-07-15 2007-07-16 Cognate Therapeutics Inc The immunophenotype and immunogenicity of human adipose derived cells
US20090093403A1 (en) 2007-03-01 2009-04-09 Feng Zhang Systems, methods and compositions for optical stimulation of target cells
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
US8926959B2 (en) * 2005-07-22 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US10052497B2 (en) * 2005-07-22 2018-08-21 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US9278159B2 (en) * 2005-07-22 2016-03-08 The Board Of Trustees Of The Leland Stanford Junior University Light-activated cation channel and uses thereof
US9238150B2 (en) 2005-07-22 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Optical tissue interface method and apparatus for stimulating cells
US8357666B2 (en) * 2005-08-01 2013-01-22 Nupotential, Inc. Reprogramming a cell by inducing a pluripotent gene through RNA interference
US20070093439A1 (en) * 2005-10-25 2007-04-26 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
WO2007078922A2 (en) * 2005-12-30 2007-07-12 Neurotech Usa Inc. Micronized device for the delivery of biologically active molecules and methods of use thereof
US20070178137A1 (en) * 2006-02-01 2007-08-02 Toby Freyman Local control of inflammation
US9173661B2 (en) 2006-02-27 2015-11-03 Biomet Manufacturing, Llc Patient specific alignment guide with cutting surface and laser indicator
US9289253B2 (en) 2006-02-27 2016-03-22 Biomet Manufacturing, Llc Patient-specific shoulder guide
US9907659B2 (en) 2007-04-17 2018-03-06 Biomet Manufacturing, Llc Method and apparatus for manufacturing an implant
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US9113971B2 (en) 2006-02-27 2015-08-25 Biomet Manufacturing, Llc Femoral acetabular impingement guide
US9918740B2 (en) 2006-02-27 2018-03-20 Biomet Manufacturing, Llc Backup surgical instrument system and method
US7780672B2 (en) * 2006-02-27 2010-08-24 Biomet Manufacturing Corp. Femoral adjustment device and associated method
US8603180B2 (en) 2006-02-27 2013-12-10 Biomet Manufacturing, Llc Patient-specific acetabular alignment guides
US8591516B2 (en) 2006-02-27 2013-11-26 Biomet Manufacturing, Llc Patient-specific orthopedic instruments
US8070752B2 (en) * 2006-02-27 2011-12-06 Biomet Manufacturing Corp. Patient specific alignment guide and inter-operative adjustment
US9339278B2 (en) 2006-02-27 2016-05-17 Biomet Manufacturing, Llc Patient-specific acetabular guides and associated instruments
US10278711B2 (en) 2006-02-27 2019-05-07 Biomet Manufacturing, Llc Patient-specific femoral guide
US8407067B2 (en) 2007-04-17 2013-03-26 Biomet Manufacturing Corp. Method and apparatus for manufacturing an implant
US20150335438A1 (en) 2006-02-27 2015-11-26 Biomet Manufacturing, Llc. Patient-specific augments
US9345548B2 (en) 2006-02-27 2016-05-24 Biomet Manufacturing, Llc Patient-specific pre-operative planning
US7998128B2 (en) 2006-05-15 2011-08-16 Therataxis, LLC. Active delivery and flow redirection: novel devices and method of delivery of materials to patients
US20100030102A1 (en) * 2006-05-15 2010-02-04 David Poston Active Delivery and Flow Redirections: Novel Devices and Method of Delivery of Materials to Patients
US7695520B2 (en) * 2006-05-31 2010-04-13 Biomet Manufacturing Corp. Prosthesis and implementation system
JP2009539370A (ja) 2006-06-07 2009-11-19 オタゴ イノベーション リミテッド 診断方法およびマーカー
US9795399B2 (en) 2006-06-09 2017-10-24 Biomet Manufacturing, Llc Patient-specific knee alignment guide and associated method
AU2007275764B2 (en) 2006-07-18 2013-11-14 University Of Utah Research Foundation Methods for treating pain and screening analgesic compounds
WO2008086470A1 (en) 2007-01-10 2008-07-17 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
DK2114167T3 (en) 2007-01-16 2018-09-17 Univ Rochester NON-HUMAN ANIMALS WITH HUMAN GLIAKIMARY BRAIN
US8401609B2 (en) * 2007-02-14 2013-03-19 The Board Of Trustees Of The Leland Stanford Junior University System, method and applications involving identification of biological circuits such as neurological characteristics
US20100196328A1 (en) * 2007-04-25 2010-08-05 Tonya Bliss ISCHEMIA-INDUCED NEOVASCULARIZATION IS ENHANCED BY hCNS-SC TRANSPLANTATION
US10434327B2 (en) 2007-10-31 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Implantable optical stimulators
US10035027B2 (en) * 2007-10-31 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Device and method for ultrasonic neuromodulation via stereotactic frame based technique
EP2274424A4 (de) 2008-04-07 2012-02-01 Nupotential Inc Neuprogrammierung einer zelle mittels induzierung eines pluripotenten gens anhand der verwendung eines hdac-modulators
CA2722278C (en) 2008-04-23 2020-03-31 Feng Zhang Systems, methods and compositions for optical stimulation of target cells
MX2010012986A (es) * 2008-05-29 2011-05-25 Univ Leland Stanford Junior Linea de celulas, sistema y metodo para control optico de mensajeros secundarios.
BRPI0915583A2 (pt) * 2008-06-17 2016-01-26 Univ Leland Stanford Junior aparelho e métodos para controle do desenvolvimento celular
CA2728238C (en) 2008-06-17 2019-03-12 M. Bret Schneider Methods, systems and devices for optical stimulation of target cells using an optical transmission element
WO2010006049A1 (en) 2008-07-08 2010-01-14 The Board Of Trustees Of The Leland Stanford Junior University Materials and approaches for optical stimulation of the peripheral nervous system
NZ602416A (en) 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
EP3187581A1 (de) 2008-12-23 2017-07-05 BOCO Silicon Valley, Inc. Zielpopulationen von oligodendrozyten-vorläuferzellen und verfahren zur herstellung und verwendung davon
WO2010111278A1 (en) 2009-03-23 2010-09-30 The Texas A&M University System Compositions of mesenchymal stem cells to regenerate bone
BRPI0902039B8 (pt) 2009-06-09 2021-05-25 Anhanguera Educacional Ltda composição farmacêutica e uso de composição farmacêutica para o tratamento, profilaxia ou prevenção de doenças neoplásicas em humanos e animais
US8288158B2 (en) * 2009-06-12 2012-10-16 Board Of Regents, The University Of Texas System Stem cells modified to facilitate threonine catabolism
KR102173873B1 (ko) 2009-11-12 2020-11-04 브이셀 세라퓨틱스 인코포레이티드 포자를 닮은 세포들의 계군 및 그 용도
SG183899A1 (en) 2010-03-17 2012-10-30 Univ Leland Stanford Junior Light-sensitive ion-passing molecules
WO2012016049A1 (en) 2010-07-28 2012-02-02 Neuralstem, Inc. Methods for treating and/or reversing neurodegenerative diseases and/or disorders
AU2011307488B2 (en) 2010-10-01 2015-08-20 Hoba Therapeutics Aps Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
CN106422081B (zh) 2010-11-05 2019-06-21 斯坦福大学托管董事会 用于光遗传学方法的光的上转换
EP3486253A1 (de) 2010-11-05 2019-05-22 The Board of Trustees of The Leland Stanford Junior University Lichtaktivierte chimäre opsine und verwendungsverfahren dafür
CN106106368A (zh) 2010-11-05 2016-11-16 斯坦福大学托管董事会 光控cns功能障碍
US10086012B2 (en) 2010-11-05 2018-10-02 The Board Of Trustees Of The Leland Stanford Junior University Control and characterization of memory function
EP3225108A1 (de) 2010-11-05 2017-10-04 The Board of Trustees of The Leland Stanford Junior University Optogenetische steuerung eines verhaltens in zusammenhang mit belohnungen
ES2684307T3 (es) 2010-11-05 2018-10-02 The Board Of Trustees Of The Leland Stanford Junior University Proteínas estabilizadas de tipo opsina de función escalonada y métodos de uso de las mismas
US8696722B2 (en) 2010-11-22 2014-04-15 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic magnetic resonance imaging
US9968376B2 (en) 2010-11-29 2018-05-15 Biomet Manufacturing, Llc Patient-specific orthopedic instruments
US9241745B2 (en) 2011-03-07 2016-01-26 Biomet Manufacturing, Llc Patient-specific femoral version guide
CA2859364C (en) 2011-12-16 2019-05-07 The Board Of Trustees Of The Leland Stanford Junior University Opsin polypeptides and methods of use thereof
CA2865296A1 (en) 2012-02-21 2013-08-29 Karl A. DEISSEROTH Compositions and methods for treating neurogenic disorders of the pelvic floor
EP2968997B1 (de) 2013-03-15 2019-06-26 The Board of Trustees of the Leland Stanford Junior University Optogenetische steuerung des verhaltenszustandes
US9636380B2 (en) 2013-03-15 2017-05-02 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of inputs to the ventral tegmental area
US9790468B2 (en) 2013-03-15 2017-10-17 Avita Iinternational Ltd. Multifunctional immature dental pulp stem cells and therapeutic applications
AU2014256876B2 (en) 2013-04-26 2020-11-12 Cornell, University Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells
WO2014179331A2 (en) 2013-04-29 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Devices, systems and methods for optogenetic modulation of action potentials in target cells
TWI686205B (zh) 2013-05-31 2020-03-01 美國猶他大學研究基金會 芋螺毒素(conotoxin)肽,其醫藥組合物及用途
US9982236B2 (en) 2013-06-13 2018-05-29 Orgenesis Ltd. Cell populations, methods of transdifferentiation and methods of use thereof
WO2015023782A1 (en) 2013-08-14 2015-02-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for controlling pain
US10779519B2 (en) 2014-05-13 2020-09-22 University Of Rochester Human glial chimeric model for drug candidate assessment in human gliotrophic viral infections and progressive multifocal encephalopathy
EP3209306B1 (de) 2014-10-20 2024-04-24 Neuralstem, Inc. Stabile neurale stammzellen mit einem exogenen polynukleotid zur codierung eines wachstumsfaktors und verfahren zur verwendung davon
MA41296A (fr) 2014-12-30 2017-11-07 Orgenesis Ltd Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
US10568516B2 (en) 2015-06-22 2020-02-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
US10722310B2 (en) 2017-03-13 2020-07-28 Zimmer Biomet CMF and Thoracic, LLC Virtual surgery planning system and method
US11294165B2 (en) 2017-03-30 2022-04-05 The Board Of Trustees Of The Leland Stanford Junior University Modular, electro-optical device for increasing the imaging field of view using time-sequential capture
WO2018207179A1 (en) 2017-05-08 2018-11-15 Orgenesis Ltd. Transdifferentiated cell populations and methods of use thereof
WO2019246262A2 (en) 2018-06-21 2019-12-26 University Of Rochester Methods of treating or inhibiting onset of huntington's disease
US20230057355A1 (en) 2019-02-13 2023-02-23 University Of Rochester Gene networks that mediate remyelination of the human brain
AU2022269279A1 (en) 2021-05-06 2023-11-30 Hoba Therapeutics Aps Prevention and treatment of chemotherapy-induced neuropathic pain
CA3234809A1 (en) 2021-10-20 2023-04-27 Steven Goldman Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss
CA3235105A1 (en) 2021-10-20 2023-04-27 Steven A. Goldman Humanized chimeras for the prospective assessment of glial cell addition or replacement therapy
US20230270818A1 (en) 2021-11-02 2023-08-31 University Of Rochester Tcf7l2 mediated remyelination in the brain
WO2023104960A1 (en) 2021-12-10 2023-06-15 Hoba Therapeutics Aps Treatment of nociceptive pain
WO2023215455A1 (en) 2022-05-05 2023-11-09 University Of Rochester Dual macroglial-microglial approach towards therapeutic cell replacement in neurodegenerative and neuropsychiatric disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497796A (en) * 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals

Also Published As

Publication number Publication date
US5082670A (en) 1992-01-21
CA2005567C (en) 2005-07-26
ATE184797T1 (de) 1999-10-15
EP0449948A4 (en) 1991-11-13
JPH04503351A (ja) 1992-06-18
DE68929077D1 (de) 1999-10-28
EP0449948B1 (de) 1999-09-22
EP0449948A1 (de) 1991-10-09
WO1990006757A1 (en) 1990-06-28
CA2005567A1 (en) 1990-06-15

Similar Documents

Publication Publication Date Title
DE68929077T2 (de) Transplantieren von genetisch modifizierten zellen zur behandlung von krankheiten des zentralen nervensystems
ATE175442T1 (de) Therapie des zentralnervensystems mit genetisch modifizierten zellen
PT87394A (pt) Process for plant tissue transformation
DE69020850D1 (de) Pflanzengewebekulturverfahren zur Transformation von Pflanzenzellen.
DK442688A (da) Fremgangsmaade og praeparat til behandling af non-ige-medierede lidelser
GR1000039B (el) Ενεργος ειδικη ανοσοαναστολη.
ATE142266T1 (de) Verfahren zum transport von molekülen in eukaryotenzellen
DE69329344T2 (de) Spezifische modulationen des immunsystems
SE8800157D0 (sv) Transformation and foreign gene expression in brassica species
DE122011100046I1 (de) In vitro kulturprozess fur verschiedene stadien von gewebeparasiten.
WO1998039363A3 (en) Immunotoxins and methods of inducing immune tolerance
DE69432832D1 (de) Vorrichtung und verfahren zur photoaktivierung
ES2085928T3 (es) Gen y secuencia proteica del mk humano.
HU904966D0 (en) Process for the production of medical preparations for the treating of cardial and vascular hypertrophy and hyperplasia
FI913266A0 (fi) Foerfarande foer infoerande av exogen dna i djurets somatiska och groddceller.
DE68911693T2 (de) Pharmazeutisches mittel für behandlung von menschlichem krebs und verfahren zu seiner herstellung.
IT7923414A0 (it) Processo di produzione di proteine mediante espressione dei geni corrispondenti in batteri e vettori suscettibili d'essere messi in opera in tali processi.
ES8604990A1 (es) Procedimiento para la inactivacion de sustancias que provocan reacciones de incompatibilidad en productos sanguineos
ATE180277T1 (de) Zur behandlung von tumoren und hiv-infektionen nützliches pflanzliches protein
ES449890A1 (es) Procedimiento para el tratamiento de proteina de celula sim-ple.
ES2059401T3 (es) Procedimiento microbiologico para la obtencion de una proteina mediante cultivo de una cepa bacteriana mutante.
DE3485773T2 (de) Aus kultivierten mesenchymzellen extrahierte makromolekuele zur behandlung von degenerationskrankheiten.
NO870468D0 (no) Fremgangsmaate og apparat for oppdrett av fisk i naturlige vannsamlinger.
NO161596C (no) Fremgangsmaate for gjenvinning av proteiner og andre naeringsstoffer fra proteinholdig vann.
DE19881189D2 (de) Verfahren zum Herstellen von weitgehend nebenwirkungsfreien Kontrastmitteln

Legal Events

Date Code Title Description
8364 No opposition during term of opposition